Efficacy and Safety of a Fixed Combination Phytomedicine in the Treatment of the Common Cold (Acute Viral Respiratory Tract Infection): Results of a Randomised, Double Blind, Placebo Controlled, Multicentre Study
Summary Objective The common cold (acute viral respiratory tract infection) is one of the most frequent diseases in man, world-wide. Clinically relevant efficacy should include early improvement of all symptoms. Results of a clinical trial of a commercially available fixed combination herbal remedy...
Gespeichert in:
| Veröffentlicht in: | Current medical research and opinion 1999, Vol.15 (3), p.214-227 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 227 |
|---|---|
| container_issue | 3 |
| container_start_page | 214 |
| container_title | Current medical research and opinion |
| container_volume | 15 |
| creator | Henneicke-Von Zepelin, H. H. Hentschel, C. Schnitker, J. Kohnen, R. Köhler, G. Wüstenberg, P. (on behalf of the study group) |
| description | Summary
Objective The common cold (acute viral respiratory tract infection) is one of the most frequent diseases in man, world-wide. Clinically relevant efficacy should include early improvement of all symptoms. Results of a clinical trial of a commercially available fixed combination herbal remedy (Radix echinaceae, Radix baptisiae, Herba thujaej are reported here. The aim of this study was to verify clinical efficacy shown in recent studies under (i) good clinical practice (GCP) quality assurance and (ii) common situations at family doctors.
Methods Patients attending one of 15 study centres (practitioners) as a result of an acute common cold were randomised to the double-blind placebo-controlled study. Three tablets of study medication were applied t.i.d. for 7 to 9 days. Patients daily documented the intensity of 18 cold symptoms, as well as the cold overall, using a 10-point scale and estimated their general well-being using the Welzel-Kohnen colour scales. Additionally, the severity of illness was assessed by the physician on days 4 and 8 (CGI-1). The main and confirmatory outcome measure was expressed as a total efficacy value. This was gauged from the z-standardised AUC values of the primary endpoints (rhinitis score, bronchitis score, CGI-1 and general well-being). Adverse events, overall tolerability, vital signs and laboratory parameters were documented.
Results 263 patients were included. For safety analysis, all patients were used. 259 patients were evaluable for primary efficacy analysis (ITT). Results were confirmed analysing only the 238 valid cases (VCs). The primary efficacy parameters showed the superiority of the herbal remedy over placebo (p < 0.05). Effect size was 20.6% of the standard deviation (90% CI: 0.04-41.1%; ITT) and 23.1%, (1.7-44.5%; VC). In relation to the general well-being, the effect size was 33.9%o of the standard deviation (12.5-55.3%; VC). Patients who suffered from at least moderate symptom intensity at baseline showed response rates (at least 50% improvement of the global score, day 5) of 55.3% in the herbal remedy group and 27.3% in the placebo group (p - 0.017; NNT = 3.5). In the subgroup of patients who started therapy at an early phase of then-cold, the efficacy of the herbal remedy was most prominent (p = 0.014 for the primary efficacy parameter). The therapeutic benefit of the herbal remedy had already occurred on day 2 and reached significance (p < 0.05) on day 4, and continued until the end of the treatment |
| doi_str_mv | 10.1185/03007999909114094 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_207971344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>45817495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-4265dc6c0d8abe0af3c4c2c7eb13bac2040884f19737a56993d2a9bc1c1b1fc53</originalsourceid><addsrcrecordid>eNp9kVtrFTEUhQdRbK3-AF8kiIiCR5O5R32px1YLFUtbfR327NnhpGSSmmTQ-Z_-IDOcSr2gecntWysrrCy7L_hzIdrqBS84b2QaXApRclneyHZF2RSrsm2am9nucr9KQLWT3QnhgnORt1LeznYEr3Mhc7mbfT9QSiPgzMAO7AwUxZk5xYAd6m80sLUbe20hamfZyWaObqRBo7bEtGVxQ-zcE8SRbFxUy0FSjAleOzOwJ_s4RWKftQfDTilcpkV0fk4qwMiOrCJcrJ--XG4nE8P27dMUxo060PCMvXVTb4i9Mdqm3YkBpN4lexu9M2YhPiShxhTBEzuL0zDfzW4pMIHuXc172afDg_P1-9Xxx3dH6_3jFZZVG1dlXlcD1siHFnrioAosMceGelH0gDkveduWSsimaKCqpSyGHGSPAkUvFFbFXvZ463vp3ZeJQuxSZiRjwJKbQlfLom04bxP48A_wwk3epmxdnhpsRFGWCRJbCL0LwZPqLr0ewc-d4N3Sd_dX30nz4Mp46lMzvyi2BSfg0RUAAcEoDxZ1uOZkW9X14vN6i2mrnB_hq_Nm6CLMxvmfmuJ_MV79Jt8QmLhB8HT90X-rfwDsU9n-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>207971344</pqid></control><display><type>article</type><title>Efficacy and Safety of a Fixed Combination Phytomedicine in the Treatment of the Common Cold (Acute Viral Respiratory Tract Infection): Results of a Randomised, Double Blind, Placebo Controlled, Multicentre Study</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Henneicke-Von Zepelin, H. H. ; Hentschel, C. ; Schnitker, J. ; Kohnen, R. ; Köhler, G. ; Wüstenberg, P. ; (on behalf of the study group)</creator><creatorcontrib>Henneicke-Von Zepelin, H. H. ; Hentschel, C. ; Schnitker, J. ; Kohnen, R. ; Köhler, G. ; Wüstenberg, P. ; (on behalf of the study group)</creatorcontrib><description>Summary
Objective The common cold (acute viral respiratory tract infection) is one of the most frequent diseases in man, world-wide. Clinically relevant efficacy should include early improvement of all symptoms. Results of a clinical trial of a commercially available fixed combination herbal remedy (Radix echinaceae, Radix baptisiae, Herba thujaej are reported here. The aim of this study was to verify clinical efficacy shown in recent studies under (i) good clinical practice (GCP) quality assurance and (ii) common situations at family doctors.
Methods Patients attending one of 15 study centres (practitioners) as a result of an acute common cold were randomised to the double-blind placebo-controlled study. Three tablets of study medication were applied t.i.d. for 7 to 9 days. Patients daily documented the intensity of 18 cold symptoms, as well as the cold overall, using a 10-point scale and estimated their general well-being using the Welzel-Kohnen colour scales. Additionally, the severity of illness was assessed by the physician on days 4 and 8 (CGI-1). The main and confirmatory outcome measure was expressed as a total efficacy value. This was gauged from the z-standardised AUC values of the primary endpoints (rhinitis score, bronchitis score, CGI-1 and general well-being). Adverse events, overall tolerability, vital signs and laboratory parameters were documented.
Results 263 patients were included. For safety analysis, all patients were used. 259 patients were evaluable for primary efficacy analysis (ITT). Results were confirmed analysing only the 238 valid cases (VCs). The primary efficacy parameters showed the superiority of the herbal remedy over placebo (p < 0.05). Effect size was 20.6% of the standard deviation (90% CI: 0.04-41.1%; ITT) and 23.1%, (1.7-44.5%; VC). In relation to the general well-being, the effect size was 33.9%o of the standard deviation (12.5-55.3%; VC). Patients who suffered from at least moderate symptom intensity at baseline showed response rates (at least 50% improvement of the global score, day 5) of 55.3% in the herbal remedy group and 27.3% in the placebo group (p - 0.017; NNT = 3.5). In the subgroup of patients who started therapy at an early phase of then-cold, the efficacy of the herbal remedy was most prominent (p = 0.014 for the primary efficacy parameter). The therapeutic benefit of the herbal remedy had already occurred on day 2 and reached significance (p < 0.05) on day 4, and continued until the end of the treatment in the total score of symptoms, bronchitis score and rhinitis score, as well as in the patients' overall rating of the cold intensity. At that time, equal levels of improvement were reached three days earlier in the verum group than in the placebo group. In 26 patients receiving the herbal remedy and 23 patients receiving placebo, adverse events were reported. Adverse drug reactions were suspected in two patients in the verum group and in four patients in the placebo group. Serious adverse events did not occur.
Conclusions This study shows that the herbal remedy is effective and safe. The therapeutic benefit consists of a rapid onset of improvement of cold symptoms. If patients with colds are able to start the application of the herbal remedy as soon as practical after the occurrence of the initial symptoms, the benefit would be expected to increase (e.g. self-medication).</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1185/03007999909114094</identifier><identifier>PMID: 10621929</identifier><identifier>CODEN: CMROCX</identifier><language>eng</language><publisher>Reading: Informa UK Ltd</publisher><subject>Adult ; Aged ; Analysis of Variance ; Baptisia radix ; Biological and medical sciences ; Common cold ; Common Cold - drug therapy ; Consumer Product Safety ; Double-Blind Method ; Drug Combinations ; Echinacea ; Echinacea radix ; Female ; Fixed combinations ; General pharmacology ; Herbal remedies ; Humans ; Male ; Medical sciences ; Middle Aged ; Patient Compliance ; Pharmacognosy. Homeopathy. Health food ; Pharmacology. Drug treatments ; Phytomedicines ; Phytotherapy ; Plant Extracts - therapeutic use ; Plants, Medicinal ; Randomised clinical trials ; Therapy ; Thuja herba</subject><ispartof>Current medical research and opinion, 1999, Vol.15 (3), p.214-227</ispartof><rights>1999 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1999</rights><rights>1999 INIST-CNRS</rights><rights>Copyright Librapharm 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-4265dc6c0d8abe0af3c4c2c7eb13bac2040884f19737a56993d2a9bc1c1b1fc53</citedby><cites>FETCH-LOGICAL-c458t-4265dc6c0d8abe0af3c4c2c7eb13bac2040884f19737a56993d2a9bc1c1b1fc53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1185/03007999909114094$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1185/03007999909114094$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1985664$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10621929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Henneicke-Von Zepelin, H. H.</creatorcontrib><creatorcontrib>Hentschel, C.</creatorcontrib><creatorcontrib>Schnitker, J.</creatorcontrib><creatorcontrib>Kohnen, R.</creatorcontrib><creatorcontrib>Köhler, G.</creatorcontrib><creatorcontrib>Wüstenberg, P.</creatorcontrib><creatorcontrib>(on behalf of the study group)</creatorcontrib><title>Efficacy and Safety of a Fixed Combination Phytomedicine in the Treatment of the Common Cold (Acute Viral Respiratory Tract Infection): Results of a Randomised, Double Blind, Placebo Controlled, Multicentre Study</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>Summary
Objective The common cold (acute viral respiratory tract infection) is one of the most frequent diseases in man, world-wide. Clinically relevant efficacy should include early improvement of all symptoms. Results of a clinical trial of a commercially available fixed combination herbal remedy (Radix echinaceae, Radix baptisiae, Herba thujaej are reported here. The aim of this study was to verify clinical efficacy shown in recent studies under (i) good clinical practice (GCP) quality assurance and (ii) common situations at family doctors.
Methods Patients attending one of 15 study centres (practitioners) as a result of an acute common cold were randomised to the double-blind placebo-controlled study. Three tablets of study medication were applied t.i.d. for 7 to 9 days. Patients daily documented the intensity of 18 cold symptoms, as well as the cold overall, using a 10-point scale and estimated their general well-being using the Welzel-Kohnen colour scales. Additionally, the severity of illness was assessed by the physician on days 4 and 8 (CGI-1). The main and confirmatory outcome measure was expressed as a total efficacy value. This was gauged from the z-standardised AUC values of the primary endpoints (rhinitis score, bronchitis score, CGI-1 and general well-being). Adverse events, overall tolerability, vital signs and laboratory parameters were documented.
Results 263 patients were included. For safety analysis, all patients were used. 259 patients were evaluable for primary efficacy analysis (ITT). Results were confirmed analysing only the 238 valid cases (VCs). The primary efficacy parameters showed the superiority of the herbal remedy over placebo (p < 0.05). Effect size was 20.6% of the standard deviation (90% CI: 0.04-41.1%; ITT) and 23.1%, (1.7-44.5%; VC). In relation to the general well-being, the effect size was 33.9%o of the standard deviation (12.5-55.3%; VC). Patients who suffered from at least moderate symptom intensity at baseline showed response rates (at least 50% improvement of the global score, day 5) of 55.3% in the herbal remedy group and 27.3% in the placebo group (p - 0.017; NNT = 3.5). In the subgroup of patients who started therapy at an early phase of then-cold, the efficacy of the herbal remedy was most prominent (p = 0.014 for the primary efficacy parameter). The therapeutic benefit of the herbal remedy had already occurred on day 2 and reached significance (p < 0.05) on day 4, and continued until the end of the treatment in the total score of symptoms, bronchitis score and rhinitis score, as well as in the patients' overall rating of the cold intensity. At that time, equal levels of improvement were reached three days earlier in the verum group than in the placebo group. In 26 patients receiving the herbal remedy and 23 patients receiving placebo, adverse events were reported. Adverse drug reactions were suspected in two patients in the verum group and in four patients in the placebo group. Serious adverse events did not occur.
Conclusions This study shows that the herbal remedy is effective and safe. The therapeutic benefit consists of a rapid onset of improvement of cold symptoms. If patients with colds are able to start the application of the herbal remedy as soon as practical after the occurrence of the initial symptoms, the benefit would be expected to increase (e.g. self-medication).</description><subject>Adult</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Baptisia radix</subject><subject>Biological and medical sciences</subject><subject>Common cold</subject><subject>Common Cold - drug therapy</subject><subject>Consumer Product Safety</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Echinacea</subject><subject>Echinacea radix</subject><subject>Female</subject><subject>Fixed combinations</subject><subject>General pharmacology</subject><subject>Herbal remedies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Patient Compliance</subject><subject>Pharmacognosy. Homeopathy. Health food</subject><subject>Pharmacology. Drug treatments</subject><subject>Phytomedicines</subject><subject>Phytotherapy</subject><subject>Plant Extracts - therapeutic use</subject><subject>Plants, Medicinal</subject><subject>Randomised clinical trials</subject><subject>Therapy</subject><subject>Thuja herba</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kVtrFTEUhQdRbK3-AF8kiIiCR5O5R32px1YLFUtbfR327NnhpGSSmmTQ-Z_-IDOcSr2gecntWysrrCy7L_hzIdrqBS84b2QaXApRclneyHZF2RSrsm2am9nucr9KQLWT3QnhgnORt1LeznYEr3Mhc7mbfT9QSiPgzMAO7AwUxZk5xYAd6m80sLUbe20hamfZyWaObqRBo7bEtGVxQ-zcE8SRbFxUy0FSjAleOzOwJ_s4RWKftQfDTilcpkV0fk4qwMiOrCJcrJ--XG4nE8P27dMUxo060PCMvXVTb4i9Mdqm3YkBpN4lexu9M2YhPiShxhTBEzuL0zDfzW4pMIHuXc172afDg_P1-9Xxx3dH6_3jFZZVG1dlXlcD1siHFnrioAosMceGelH0gDkveduWSsimaKCqpSyGHGSPAkUvFFbFXvZ463vp3ZeJQuxSZiRjwJKbQlfLom04bxP48A_wwk3epmxdnhpsRFGWCRJbCL0LwZPqLr0ewc-d4N3Sd_dX30nz4Mp46lMzvyi2BSfg0RUAAcEoDxZ1uOZkW9X14vN6i2mrnB_hq_Nm6CLMxvmfmuJ_MV79Jt8QmLhB8HT90X-rfwDsU9n-</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>Henneicke-Von Zepelin, H. H.</creator><creator>Hentschel, C.</creator><creator>Schnitker, J.</creator><creator>Kohnen, R.</creator><creator>Köhler, G.</creator><creator>Wüstenberg, P.</creator><creator>(on behalf of the study group)</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Librapharm</general><general>Informa Healthcare</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>1999</creationdate><title>Efficacy and Safety of a Fixed Combination Phytomedicine in the Treatment of the Common Cold (Acute Viral Respiratory Tract Infection): Results of a Randomised, Double Blind, Placebo Controlled, Multicentre Study</title><author>Henneicke-Von Zepelin, H. H. ; Hentschel, C. ; Schnitker, J. ; Kohnen, R. ; Köhler, G. ; Wüstenberg, P. ; (on behalf of the study group)</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-4265dc6c0d8abe0af3c4c2c7eb13bac2040884f19737a56993d2a9bc1c1b1fc53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Baptisia radix</topic><topic>Biological and medical sciences</topic><topic>Common cold</topic><topic>Common Cold - drug therapy</topic><topic>Consumer Product Safety</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Echinacea</topic><topic>Echinacea radix</topic><topic>Female</topic><topic>Fixed combinations</topic><topic>General pharmacology</topic><topic>Herbal remedies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Patient Compliance</topic><topic>Pharmacognosy. Homeopathy. Health food</topic><topic>Pharmacology. Drug treatments</topic><topic>Phytomedicines</topic><topic>Phytotherapy</topic><topic>Plant Extracts - therapeutic use</topic><topic>Plants, Medicinal</topic><topic>Randomised clinical trials</topic><topic>Therapy</topic><topic>Thuja herba</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Henneicke-Von Zepelin, H. H.</creatorcontrib><creatorcontrib>Hentschel, C.</creatorcontrib><creatorcontrib>Schnitker, J.</creatorcontrib><creatorcontrib>Kohnen, R.</creatorcontrib><creatorcontrib>Köhler, G.</creatorcontrib><creatorcontrib>Wüstenberg, P.</creatorcontrib><creatorcontrib>(on behalf of the study group)</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Henneicke-Von Zepelin, H. H.</au><au>Hentschel, C.</au><au>Schnitker, J.</au><au>Kohnen, R.</au><au>Köhler, G.</au><au>Wüstenberg, P.</au><au>(on behalf of the study group)</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of a Fixed Combination Phytomedicine in the Treatment of the Common Cold (Acute Viral Respiratory Tract Infection): Results of a Randomised, Double Blind, Placebo Controlled, Multicentre Study</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>1999</date><risdate>1999</risdate><volume>15</volume><issue>3</issue><spage>214</spage><epage>227</epage><pages>214-227</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><coden>CMROCX</coden><abstract>Summary
Objective The common cold (acute viral respiratory tract infection) is one of the most frequent diseases in man, world-wide. Clinically relevant efficacy should include early improvement of all symptoms. Results of a clinical trial of a commercially available fixed combination herbal remedy (Radix echinaceae, Radix baptisiae, Herba thujaej are reported here. The aim of this study was to verify clinical efficacy shown in recent studies under (i) good clinical practice (GCP) quality assurance and (ii) common situations at family doctors.
Methods Patients attending one of 15 study centres (practitioners) as a result of an acute common cold were randomised to the double-blind placebo-controlled study. Three tablets of study medication were applied t.i.d. for 7 to 9 days. Patients daily documented the intensity of 18 cold symptoms, as well as the cold overall, using a 10-point scale and estimated their general well-being using the Welzel-Kohnen colour scales. Additionally, the severity of illness was assessed by the physician on days 4 and 8 (CGI-1). The main and confirmatory outcome measure was expressed as a total efficacy value. This was gauged from the z-standardised AUC values of the primary endpoints (rhinitis score, bronchitis score, CGI-1 and general well-being). Adverse events, overall tolerability, vital signs and laboratory parameters were documented.
Results 263 patients were included. For safety analysis, all patients were used. 259 patients were evaluable for primary efficacy analysis (ITT). Results were confirmed analysing only the 238 valid cases (VCs). The primary efficacy parameters showed the superiority of the herbal remedy over placebo (p < 0.05). Effect size was 20.6% of the standard deviation (90% CI: 0.04-41.1%; ITT) and 23.1%, (1.7-44.5%; VC). In relation to the general well-being, the effect size was 33.9%o of the standard deviation (12.5-55.3%; VC). Patients who suffered from at least moderate symptom intensity at baseline showed response rates (at least 50% improvement of the global score, day 5) of 55.3% in the herbal remedy group and 27.3% in the placebo group (p - 0.017; NNT = 3.5). In the subgroup of patients who started therapy at an early phase of then-cold, the efficacy of the herbal remedy was most prominent (p = 0.014 for the primary efficacy parameter). The therapeutic benefit of the herbal remedy had already occurred on day 2 and reached significance (p < 0.05) on day 4, and continued until the end of the treatment in the total score of symptoms, bronchitis score and rhinitis score, as well as in the patients' overall rating of the cold intensity. At that time, equal levels of improvement were reached three days earlier in the verum group than in the placebo group. In 26 patients receiving the herbal remedy and 23 patients receiving placebo, adverse events were reported. Adverse drug reactions were suspected in two patients in the verum group and in four patients in the placebo group. Serious adverse events did not occur.
Conclusions This study shows that the herbal remedy is effective and safe. The therapeutic benefit consists of a rapid onset of improvement of cold symptoms. If patients with colds are able to start the application of the herbal remedy as soon as practical after the occurrence of the initial symptoms, the benefit would be expected to increase (e.g. self-medication).</abstract><cop>Reading</cop><pub>Informa UK Ltd</pub><pmid>10621929</pmid><doi>10.1185/03007999909114094</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-7995 |
| ispartof | Current medical research and opinion, 1999, Vol.15 (3), p.214-227 |
| issn | 0300-7995 1473-4877 |
| language | eng |
| recordid | cdi_proquest_journals_207971344 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Adult Aged Analysis of Variance Baptisia radix Biological and medical sciences Common cold Common Cold - drug therapy Consumer Product Safety Double-Blind Method Drug Combinations Echinacea Echinacea radix Female Fixed combinations General pharmacology Herbal remedies Humans Male Medical sciences Middle Aged Patient Compliance Pharmacognosy. Homeopathy. Health food Pharmacology. Drug treatments Phytomedicines Phytotherapy Plant Extracts - therapeutic use Plants, Medicinal Randomised clinical trials Therapy Thuja herba |
| title | Efficacy and Safety of a Fixed Combination Phytomedicine in the Treatment of the Common Cold (Acute Viral Respiratory Tract Infection): Results of a Randomised, Double Blind, Placebo Controlled, Multicentre Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T15%3A11%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20a%20Fixed%20Combination%20Phytomedicine%20in%20the%20Treatment%20of%20the%20Common%20Cold%20(Acute%20Viral%20Respiratory%20Tract%20Infection):%20Results%20of%20a%20Randomised,%20Double%20Blind,%20Placebo%20Controlled,%20Multicentre%20Study&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Henneicke-Von%20Zepelin,%20H.%20H.&rft.date=1999&rft.volume=15&rft.issue=3&rft.spage=214&rft.epage=227&rft.pages=214-227&rft.issn=0300-7995&rft.eissn=1473-4877&rft.coden=CMROCX&rft_id=info:doi/10.1185/03007999909114094&rft_dat=%3Cproquest_pubme%3E45817495%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=207971344&rft_id=info:pmid/10621929&rfr_iscdi=true |